Our scalable perfusion bioreactor technology enables stable, high-yield continuous biomanufacturing for mammalian cell culture, monoclonal antibodies, recombinant proteins, and viral vector production. Differentiated from traditional batch and fed-batch processes, this advanced continuous manufacturing system integrates real-time cell retention, fresh media feeding, and spent media harvesting to maintain high viable cell density and prolonged production longevity, significantly boosting overall process productivity.
Engineered with optimized low-shear fluid dynamics and precision closed-loop automation, the platform delivers consistent control of DO, pH, temperature, and perfusion flow rates throughout extended production cycles. Equipped with reliable cell retention systems, it minimizes cell loss while removing metabolic waste continuously, creating a stable, low-stress culture environment that enhances product titer and batch consistency.
Designed for full scalability, the perfusion technology seamlessly scales up from lab-scale process development and clinical pilot production to large-scale commercial continuous manufacturing lines. Compatible with both single-use and stainless steel bioreactor systems, it offers flexible deployment options to match diverse project layouts and budget demands.
Fully compliant with global cGMP, FDA and EMA guidelines, the system features complete data traceability, audit-ready operation, and simplified CQV validation workflows. By shortening production cycles, reducing media consumption and lowering batch-to-batch variability, our perfusion bioreactor technology effectively cuts operational costs and accelerates industrial-scale biopharmaceutical continuous manufacturing.
